InvestSMART

Acrux Limited (ASX: ACR) - Announcements

- Current share price for ACR : $0.010

ASX company news and announcements for Acrux Limited (ACR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Acrux Limited (ACR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Acrux Limited (ACR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Acrux Limited (ACR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$6 Response to ASX Price Query 18 Sep 2014 2:37PM $1.250 $0.010 fallen by 99.20%
$6 Trading Halt 18 Sep 2014 10:55AM $1.250 $0.010 fallen by 99.20%
$6 Hexima Collaboration Update 21 Aug 2014 10:28AM $2.010 $0.010 fallen by 99.50%
$6 Appendix 4E and Financial Report to 30 June 2014 21 Aug 2014 10:03AM $2.010 $0.010 fallen by 99.50%
$6 Marketing Approval Granted for Estradiol Spray South Africa 20 Aug 2014 8:56AM $1.965 $0.010 fallen by 99.49%
$6 Axiron Net Sales for the Quarter to 30 June 2014 25 Jul 2014 9:05AM $1.520 $0.010 fallen by 99.34%
$6 Acrux Appoints New CEO 25 Jul 2014 9:01AM $1.520 $0.010 fallen by 99.34%
$6 Response to ASX price query 8 Jul 2014 3:18PM $1.215 $0.010 fallen by 99.18%
$6 Axiron Net Sales for the Quarter to 31 March 2014 28 Apr 2014 9:35AM $1.105 $0.010 fallen by 99.10%
$6 Response to ASX Price Query 7 Mar 2014 9:05AM $1.980 $0.010 fallen by 99.49%
$6 Half Yearly Report and Accounts 20 Feb 2014 10:01AM $2.070 $0.010 fallen by 99.52%
$6 Response to ASX Price Query 5 Feb 2014 9:52AM $1.915 $0.010 fallen by 99.48%
$6 Trading Halt 4 Feb 2014 2:56PM $2.080 $0.010 fallen by 99.52%
$6 Axiron Net Sales for the Quarter to 31 December 2013 31 Jan 2014 9:50AM $2.320 $0.010 fallen by 99.57%
$6 Axiron Launched in Brazil 28 Nov 2013 9:39AM $2.510 $0.010 fallen by 99.60%
$6 Lilly and Acrux file lawsuit against Actavis 13 Nov 2013 9:22AM $2.590 $0.010 fallen by 99.61%
$6 Axiron net sales, quarter to 30 September 2013 24 Oct 2013 9:36AM $2.760 $0.010 fallen by 99.64%
$6 Acrux Announces First European Approval for AXIRON 7 Oct 2013 9:43AM $3.170 $0.010 fallen by 99.68%
$6 Appendix 4E and Financial Report to 30 June 2013 27 Aug 2013 9:40AM $3.260 $0.010 fallen by 99.69%
$6 Axiron net sales, quarter to 30 June 2013 25 Jul 2013 8:28AM $3.440 $0.010 fallen by 99.71%
$6 Axiron launched in Canada 28 Jun 2013 12:07PM $3.510 $0.010 fallen by 99.72%
$6 Richter to commercialise estradiol spray in ex-US markets 27 Jun 2013 8:26AM $3.540 $0.010 fallen by 99.72%
$6 Axiron net sales, quarter to 31 March 2013 26 Apr 2013 8:28AM $4.120 $0.010 fallen by 99.76%
$6 Acrux provides half-year update 18 Feb 2013 9:30AM $3.860 $0.010 fallen by 99.74%
$6 Half Yearly Report and Accounts 18 Feb 2013 9:24AM $3.860 $0.010 fallen by 99.74%

526 - 550 of 699 results

Page 22 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.